Cargando…
Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
Despite efforts to improve earlier diagnosis of non-small cell lung cancer (NSCLC), most patients present with advanced stage disease, which is often associated with poor survival outcomes with only 15% surviving for 5 years from their diagnosis. Tumour tissue biopsy is the current mainstream for ca...
Autores principales: | Kapeleris, Joanna, Ebrahimi Warkiani, Majid, Kulasinghe, Arutha, Vela, Ian, Kenny, Liz, Ladwa, Rahul, O’Byrne, Kenneth, Punyadeera, Chamindie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965052/ https://www.ncbi.nlm.nih.gov/pubmed/35372000 http://dx.doi.org/10.3389/fonc.2022.859152 |
Ejemplares similares
-
The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer
por: Kapeleris, Joanna, et al.
Publicado: (2018) -
Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer
por: Kapeleris, Joanna, et al.
Publicado: (2020) -
Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets
por: Kulasinghe, Arutha, et al.
Publicado: (2019) -
PD-L1 expressing circulating tumour cells in head and neck cancers
por: Kulasinghe, Arutha, et al.
Publicado: (2017) -
The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells
por: Kulasinghe, Arutha, et al.
Publicado: (2020)